C2Dx buys Hemostatix and its thermal scalpel

C2Dx has acquired Hemostatix Medical Technologies, gaining a thermal scalpel system that will become the company’s third product line.

The Hemostatix Thermal Scalpel seals blood vessels as they’re cut, effectively cutting and coagulating simultaneously. The scalpel features a five-layer laminate composition of copper and stainless steel. Surgeons can use it to prioritize safety with no muscle excitation, reduced blood loss, and move toward a smoke-free operating room.

C2Dx was founded in early 2019 by CEO Kevin McLeod and Plymouth Growth.

“Our leadership team has extensive experience leading all phases of medical device manufacturing. We have seen great success with both the STIC and T/Pump and are looking forward to applying our innovative strategy to this new product line,” McLeod told the press. “The latest acquisition of Hemostatix offers an exciting chance for us to expand our product offering and grow our team as we further pursue C2Dx’s mission.”

Brad Beale, former co-owner of Hemostatix added, “C2Dx’s acquisition of Hemostatix provides a great growth opportunity for the product as well as our team. We are looking forward to providing extended service offerings to our customers as we develop the product through the combined expertise of these two companies.” Brad joins C2Dx as General Manager of the Hemostatix operations.

The expanded business will serve new specialties and procedures around the globe. Medical Product Outsourcing